Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
12
|
pubmed:dateCreated |
1996-9-24
|
pubmed:abstractText |
Fluoxetine (F) is a specific serotonin-reuptake inhibitor that has been shown to promote weight loss and improve glycemic control in obese diabetic patients. To study its long-term metabolic effect, 40 obese patients with non-insulin -dependent diabetes mellitus (NIDDM) or impaired glucose tolerance (IGT) were included in a 12-month, randomized, placebo controlled study. Patients were assigned to receive either 60 mg F or placebo (P) daily in conjunction with a 5.0-MJ/d diet (> 50% carbohydrate). Both groups showed a significant weight loss, with a nadir after 6 months without group differences (mean +/- SD: F, 10.1 +/- 10.0 kg; P, 9.4 +/- 11.5 kg). Fifteen patients from the F group and 14 from the P group completed the 12-month study without weight loss differences. Glycemic regulation improved along with the weight loss, but with a larger decline in plasma C-peptide and fasting glucose levels on the F group (P < .05). Total skeletal muscle glycogen synthase (GS) activity increased by 31% in the F group (P < .01) and by 17% in the P group (nonsignificant) after 6 months of treatment, but was still less than the activity in normal-weight controls (aged 28.0 +/- 6.3 years; body mass index, 23.5 +/- 2.2). After adjustment for fasting glucose, insulin, weight loss, and diabetic state, a positive effect of F remained on the total GS activity, which accounted for 27% of the variation (P < .05). The waist to hip ratio was reduced in P subjects as compared with F subjects (P < .05). Fat-free mass (FFM) tended to be more reduced in the F group as compared with P subjects (4.9 v 1.9 kg), although the difference did not reach statistical significance. In conclusion, F seems to improve insulin sensitivity beyond the effect mediated through weight loss by a possible effect on GS activity in skeletal muscle tissue.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Blood Glucose,
http://linkedlifedata.com/resource/pubmed/chemical/Fluoxetine,
http://linkedlifedata.com/resource/pubmed/chemical/Glycogen Synthase,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Insulin,
http://linkedlifedata.com/resource/pubmed/chemical/Serotonin Uptake Inhibitors
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0026-0495
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
44
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1570-6
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:8786726-Adult,
pubmed-meshheading:8786726-Blood Glucose,
pubmed-meshheading:8786726-Body Composition,
pubmed-meshheading:8786726-Diabetes Mellitus, Type 2,
pubmed-meshheading:8786726-Female,
pubmed-meshheading:8786726-Fluoxetine,
pubmed-meshheading:8786726-Glucose Intolerance,
pubmed-meshheading:8786726-Glycogen Synthase,
pubmed-meshheading:8786726-Humans,
pubmed-meshheading:8786726-Male,
pubmed-meshheading:8786726-Middle Aged,
pubmed-meshheading:8786726-Muscles,
pubmed-meshheading:8786726-Obesity,
pubmed-meshheading:8786726-Receptor, Insulin,
pubmed-meshheading:8786726-Serotonin Uptake Inhibitors,
pubmed-meshheading:8786726-Time Factors
|
pubmed:year |
1995
|
pubmed:articleTitle |
Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity.
|
pubmed:affiliation |
Department of Internal Medicine, Hvidovre Hospital, Denmark.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|